- Home
- IXHL vs ATNM Comparison
IXHL vs ATNM Comparison
Compare IXHL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- ATNM
- Stock Information
- Founded
- IXHL 2001
- ATNM 2000
- Country
- IXHL Australia
- ATNM United States
- Employees
- IXHL N/A
- ATNM N/A
- Industry
- IXHL
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- ATNM Health Care
- Exchange
- IXHL Nasdaq
- ATNM Nasdaq
- Market Cap
- IXHL 49.1M
- ATNM 50.2M
- IPO Year
- IXHL N/A
- ATNM N/A
- Fundamental
- Price
- IXHL $0.31
- ATNM $1.34
- Analyst Decision
- IXHL
- ATNM Strong Buy
- Analyst Count
- IXHL 0
- ATNM 1
- Target Price
- IXHL N/A
- ATNM $4.00
- AVG Volume (30 Days)
- IXHL 17.8M
- ATNM 250.0K
- Earning Date
- IXHL 11-14-2025
- ATNM 11-14-2025
- Dividend Yield
- IXHL N/A
- ATNM N/A
- EPS Growth
- IXHL N/A
- ATNM N/A
- EPS
- IXHL N/A
- ATNM N/A
- Revenue
- IXHL $12,000.00
- ATNM $90,000.00
- Revenue This Year
- IXHL $1,188.37
- ATNM N/A
- Revenue Next Year
- IXHL N/A
- ATNM N/A
- P/E Ratio
- IXHL N/A
- ATNM N/A
- Revenue Growth
- IXHL N/A
- ATNM 11.11
- 52 Week Low
- IXHL $0.08
- ATNM $1.03
- 52 Week High
- IXHL $2.25
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- IXHL 38.06
- ATNM 44.33
- Support Level
- IXHL $0.33
- ATNM $1.23
- Resistance Level
- IXHL $0.35
- ATNM $1.60
- Average True Range (ATR)
- IXHL 0.02
- ATNM 0.09
- MACD
- IXHL 0.00
- ATNM 0.01
- Stochastic Oscillator
- IXHL 17.77
- ATNM 24.32
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.